RIPK1 and sarcoma: To evaluate the possibility of harnessing RIPK1's cytotoxic potential during ILP, we combined the current standard‐of‐care treatment regimen (ILP‐TNF/Mel) with pharmacological inhibitors of IAPs (SM) and evaluated its efficacy in an immune‐competent rat model of extremity sarcoma (ESTS).